United States Biotechnology & Medical Research

AN2 Therapeutics Inc (ANTX)

Track

AN2 Therapeutics Inc. experienced two insider trading transactions over the past ninety days, both involving sales. These divestments totaled approximately 1,174 dollars. The company stock price has risen 33.7 percent recently, while the last earnings report showed a 25 percent beat on earnings per share expectations.
Ticker: ANTX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for AN2 Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 8 Jul 2026
Value US$888,720.19 | Price 491.35 | Shares 4,425 (-19.4%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-10 2026-07-08 PlS Planned sale
1.7
Eizen Joshua M

See Remarks

Officer
4,425 -19.4%
491.35
US$888,720 		4,425 -19.4% 491.35 US$888,720
2026-06-02 2026-05-29 S Sale
0.6
Williams Sarah Joanne

Principal Accounting Officer

Officer
48,946 -8.7%
163.23
US$1,754,694 		48,946 -8.7% 163.23 US$1,754,694
2026-03-05 2026-03-03 S Sale
0.6
Williams Sarah Joanne

Principal Accounting Officer

Officer
22,765 +31.4%
449.00
US$494,410 		22,765 +31.4% 449.00 US$494,410
2026-01-07 2026-01-06 S Sale
1.7
Prior Stephen David

Chief Strategy Officer

Officer
2,858 -4.6%
1.01
US$2,892 		2,858 -4.6% 1.01 US$2,892
2026-01-07 2026-01-06 PlS Planned sale
Chanda Sanjay

Chief Development Officer

Officer
5,956 -7.3%
1.01
US$6,027 		5,956 -7.3% 1.01 US$6,027
2026-01-07 2026-01-06 S Sale
1.7
Eizen Joshua M

See Remarks

Officer
6,931 -4.3%
1.01
US$7,014 		6,931 -4.3% 1.01 US$7,014
2026-01-07 2026-01-06 PlS Planned sale
Day Lucy

Chief Financial Officer

Officer
5,512 -6.8%
1.01
US$5,578 		5,512 -6.8% 1.01 US$5,578
2026-01-07 2026-01-05 S Sale
1.7
Prior Stephen David

Chief Strategy Officer

Officer
3,604 -5.5%
1.00
US$3,615 		3,604 -5.5% 1.00 US$3,615
2026-01-07 2026-01-05 PlS Planned sale
Chanda Sanjay

Chief Development Officer

Officer
3,295 -3.9%
1.00
US$3,305 		3,295 -3.9% 1.00 US$3,305
2026-01-07 2026-01-05 S Sale
1.7
Eizen Joshua M

See Remarks

Officer
17,923 -10.1%
1.00
US$17,948 		17,923 -10.1% 1.00 US$17,948
2026-01-07 2026-01-05 PlS Planned sale
Day Lucy

Chief Financial Officer

Officer
3,295 -3.9%
1.00
US$3,305 		3,295 -3.9% 1.00 US$3,305
2025-11-06 2025-11-04 PlS Planned sale
1.7
Prior Stephen David

Chief Strategy Officer

Officer
765 -1.2%
1.14
US$872 		765 -1.2% 1.14 US$872
2025-11-06 2025-11-04 PlS Planned sale
1.7
Eizen Joshua M

See Remarks

Officer
2,819 -1.6%
1.14
US$3,214 		2,819 -1.6% 1.14 US$3,214
2025-06-03 2025-06-02 B Purchase
4.1
Easom Eric

Chief Executive Officer

Executive Director
10,000 +4.1%
1.07
US$10,665 		10,000 +4.1% 1.07 US$10,665
2025-05-30 2025-05-30 S Sale
2.9
Leonard Braden Michael
Large shareholder
7,000 -0.2%
1.03
US$7,227 		7,000 -0.2% 1.03 US$7,227
2025-05-30 2025-05-30 S Sale
2.9
Leonard Braden Michael
Large shareholder
425,000 -11.6%
1.01
US$429,250 		425,000 -11.6% 1.01 US$429,250
2025-06-16 2025-05-28 S Sale
2.9
Leonard Braden Michael
Large shareholder
200,000 -6.2%
1.09
US$218,000 		200,000 -6.2% 1.09 US$218,000
2025-05-30 2025-05-28 S Sale
2.9
Leonard Braden Michael
Large shareholder
100,000 -2.7%
1.16
US$116,000 		100,000 -2.7% 1.16 US$116,000
2025-05-30 2025-05-28 S Sale
2.9
Leonard Braden Michael
Large shareholder
2,000,000 -34.8%
1.16
US$2,320,000 		2,000,000 -34.8% 1.16 US$2,320,000
2025-05-29 2025-05-28 B Purchase
1.5
FitzPatrick Margaret M
Non-Executive Director
8,610 +inf%
1.18
US$10,133 		8,610 +inf% 1.18 US$10,133
2025-01-07 2025-01-03 PlS Planned sale
Day Lucy

Chief Financial Officer

Officer
2,957 -8.3%
1.34
US$3,965 		2,957 -8.3% 1.34 US$3,965
2025-01-07 2025-01-03 PlS Planned sale
Chanda Sanjay

Chief Development Officer

Officer
2,957 -9.0%
1.34
US$3,965 		2,957 -9.0% 1.34 US$3,965
2025-01-07 2025-01-03 S Sale
1.7
Prior Stephen David

Chief Strategy Officer

Officer
2,029 -5.7%
1.34
US$2,721 		2,029 -5.7% 1.34 US$2,721
2025-01-07 2025-01-03 S Sale
1.7
Eizen Joshua M

See Remarks

Officer
9,663 -7.6%
1.34
US$12,958 		9,663 -7.6% 1.34 US$12,958
2024-12-10 2024-12-10 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
5,000 +0.8%
1.49
US$7,468 		5,000 +0.8% 1.49 US$7,468
2024-12-10 2024-12-10 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
5,000 +0.9%
1.49
US$7,462 		5,000 +0.9% 1.49 US$7,462
2024-12-10 2024-12-09 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
18,483 +2.9%
1.43
US$26,407 		18,483 +2.9% 1.43 US$26,407
2024-12-10 2024-12-09 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
12,289 +2.2%
1.43
US$17,577 		12,289 +2.2% 1.43 US$17,577
2024-12-10 2024-12-06 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
6,517 +1.0%
1.45
US$9,427 		6,517 +1.0% 1.45 US$9,427
2024-12-10 2024-12-06 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
12,711 +2.3%
1.45
US$18,367 		12,711 +2.3% 1.45 US$18,367
2024-11-27 2024-11-27 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
25,000 +4.2%
1.42
US$35,418 		25,000 +4.2% 1.42 US$35,418
2024-11-27 2024-11-27 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
25,000 +4.7%
1.42
US$35,422 		25,000 +4.7% 1.42 US$35,422
2024-11-27 2024-11-27 B Purchase
4.3
Zakrzewski Joseph S
Non-Executive Director
2,000 +1.6%
1.40
US$2,800 		2,000 +1.6% 1.40 US$2,800
2024-11-27 2024-11-26 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
12,500 +2.1%
1.39
US$17,428 		12,500 +2.1% 1.39 US$17,428
2024-11-27 2024-11-26 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
12,500 +2.4%
1.39
US$17,418 		12,500 +2.4% 1.39 US$17,418
2024-11-21 2024-11-20 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
25,000 +5.1%
1.15
US$28,870 		25,000 +5.1% 1.15 US$28,870
2024-11-21 2024-11-20 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
25,000 +4.5%
1.16
US$29,000 		25,000 +4.5% 1.16 US$29,000
2024-11-21 2024-11-19 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
75,000 +18.1%
1.04
US$77,730 		75,000 +18.1% 1.04 US$77,730
2024-11-21 2024-11-19 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
75,000 +15.5%
1.03
US$77,528 		75,000 +15.5% 1.03 US$77,528
2024-11-20 2024-11-19 B Purchase
4.3
Zakrzewski Joseph S
Non-Executive Director
5,000 +4.2%
1.01
US$5,050 		5,000 +4.2% 1.01 US$5,050
2024-11-20 2024-11-18 B Purchase
4.3
Zakrzewski Joseph S
Non-Executive Director
20,000 +20.4%
1.00
US$19,996 		20,000 +20.4% 1.00 US$19,996
2024-11-18 2024-11-18 B Purchase
4.1
Easom Eric

Chief Executive Officer

Executive Director
50,000 +4.9%
1.00
US$49,970 		50,000 +4.9% 1.00 US$49,970
2024-08-15 2024-08-15 PrS Proposed sale
RA Capital Healthcare Fund LP

Affiliate
1,699,998
1.00
US$1,699,999 		1,699,998 1.00 US$1,699,999
2024-08-15 2024-08-15 PrS Proposed sale
RA Capital Nexus Fund II, L.P.

Affiliate
299,999
1.02
US$305,998 		299,999 1.02 US$305,998
2024-08-14 2024-08-14 B Purchase
2.9
Leonard Braden Michael
Large shareholder
1,500,000 +35.3%
1.04
US$1,560,000 		1,500,000 +35.3% 1.04 US$1,560,000
2024-08-13 2024-08-09 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
114,759 -27.6%
1.08
US$123,940 		114,759 -27.6% 1.08 US$123,940
2024-08-13 2024-08-09 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
3,410,335 -66.4%
1.08
US$3,683,162 		3,410,335 -66.4% 1.08 US$3,683,162
2024-01-19 2024-01-18 S Sale
4.3
Zakrzewski Joseph S
Non-Executive Director
100,000 -19.8%
19.11
US$1,911,410 		100,000 -19.8% 19.11 US$1,911,410
2024-01-18 2024-01-18 PrS Proposed sale
4.3
Z3 TRUST

Director

Non-Executive Director
100,000
19.11
US$1,911,410 		100,000 19.11 US$1,911,410
2024-01-18 2024-01-16 S Sale
3.7
Aziz Kabeer
Non-Executive Director
15,907 -4.0%
19.65
US$312,573 		15,907 -4.0% 19.65 US$312,573
2024-01-18 2024-01-16 S Sale
3.7
Aziz Kabeer
Non-Executive Director
84,093 -4.0%
19.65
US$1,652,427 		84,093 -4.0% 19.65 US$1,652,427
2024-01-18 2024-01-16 S Sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
15,907 -4.0%
19.65
US$312,573 		15,907 -4.0% 19.65 US$312,573
2024-01-18 2024-01-16 S Sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
84,093 -4.0%
19.65
US$1,652,427 		84,093 -4.0% 19.65 US$1,652,427
2024-01-16 2024-01-16 PrS Proposed sale
Adjuvant Global Health Technology Fund DE, L.P.

Shareholder
15,907
20.88
US$332,138 		15,907 20.88 US$332,138
2024-01-16 2024-01-16 PrS Proposed sale
3.7
Adjuvant Global Health Technology Fund, L.P.

Shareholder
84,093
20.88
US$1,755,862 		84,093 20.88 US$1,755,862
2024-01-17 2024-01-12 PlS Planned sale
2.7
Readnour Robin Shane
Non-Executive Director
719 -0.1%
21.91
US$15,753 		719 -0.1% 21.91 US$15,753
2024-01-17 2024-01-12 PlS Planned sale
2.7
Readnour Robin Shane
Non-Executive Director
706 -0.2%
21.92
US$15,476 		706 -0.2% 21.92 US$15,476
2024-01-12 2024-01-10 PlS Planned sale
2.7
Readnour Robin Shane
Non-Executive Director
1,800 -0.4%
21.92
US$39,456 		1,800 -0.4% 21.92 US$39,456
2024-01-12 2024-01-10 PlS Planned sale
2.7
Readnour Robin Shane
Non-Executive Director
1,869 -0.4%
21.93
US$40,987 		1,869 -0.4% 21.93 US$40,987
2024-01-10 2024-01-10 PrS Proposed sale
MGC VENTURE PARTNERS 2018 ,LP

Officer

Officer
9,443
21.53
US$203,308 		9,443 21.53 US$203,308
2024-01-10 2024-01-10 PrS Proposed sale
MGC VENTURE PARTNERS QP 2018 ,LP

Officer

Officer
11,033
21.53
US$237,540 		11,033 21.53 US$237,540
2024-01-11 2024-01-09 PlS Planned sale
Krause Kevin Michael

Chief Strategy Officer

Officer
7,417 -79.5%
20.14
US$149,367 		7,417 -79.5% 20.14 US$149,367
2024-01-04 2024-01-02 PlS Planned sale
Krause Kevin Michael

Chief Strategy Officer

Officer
2,583 -57.4%
20.12
US$51,967 		2,583 -57.4% 20.12 US$51,967
2024-01-04 2024-01-02 PlS Planned sale
4.1
Easom Eric

Chief Executive Officer

Executive Director
2,777 -56.6%
20.09
US$55,802 		2,777 -56.6% 20.09 US$55,802
2024-01-02 2024-01-02 PrS Proposed sale
4.1
ERIC EASOM

Officer

Officer
2,777
20.49
US$56,901 		2,777 20.49 US$56,901
2024-01-02 2024-01-02 PrS Proposed sale
KEVIN KRAUSE

Officer

Officer
10,000
20.49
US$204,900 		10,000 20.49 US$204,900
2023-11-16 2023-11-14 PlS Planned sale
3.7
Aziz Kabeer
Non-Executive Director Large shareholder
288 -0.1%
16.15
US$4,650 		288 -0.1% 16.15 US$4,650
2023-11-16 2023-11-14 PlS Planned sale
3.7
Aziz Kabeer
Non-Executive Director Large shareholder
1,522 -0.1%
16.15
US$24,574 		1,522 -0.1% 16.15 US$24,574
2023-11-16 2023-11-14 PlS Planned sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
288 -0.1%
16.15
US$4,650 		288 -0.1% 16.15 US$4,650
2023-11-16 2023-11-14 PlS Planned sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
1,522 -0.1%
16.15
US$24,574 		1,522 -0.1% 16.15 US$24,574
2023-11-14 2023-11-14 PrS Proposed sale
ADJUVANT CAPITAL GP, L.P.

Officer

Officer
1,810
14.99
US$27,132 		1,810 14.99 US$27,132
2023-10-03 2023-10-02 PlS Planned sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
902 -0.2%
16.07
US$14,495 		902 -0.2% 16.07 US$14,495
2023-10-03 2023-10-02 PlS Planned sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
4,770 -0.2%
16.07
US$76,654 		4,770 -0.2% 16.07 US$76,654
2023-10-03 2023-10-02 PlS Planned sale
3.7
Aziz Kabeer
Non-Executive Director Large shareholder
902 -0.2%
16.07
US$14,495 		902 -0.2% 16.07 US$14,495
2023-10-03 2023-10-02 PlS Planned sale
3.7
Aziz Kabeer
Non-Executive Director Large shareholder
4,770 -0.2%
16.07
US$76,654 		4,770 -0.2% 16.07 US$76,654
Explore more

More insider trading research around AN2 Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America